Udo Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Udo Schneider has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Robert Biesen
Department of Rheumatology and Clinical Immunology, Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
6 shared publications - Falk Hiepe
German Rheumatology Research Center (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany
4 shared publications - Lennard Ostendorf
Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4 shared publications - Philipp Enghard
Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4 shared publications - Gerd Ruediger Burmester
Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
3 shared publications - Tobias Alexander
German Rheumatology Research Center (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany
3 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Understanding Health-related quality of life in rheumatologic diseases: insights from PROMIS® health domains
Background: Rheumatologic diseases significantly impact health-related quality of life (HRQoL), affecting physical, mental, and social well-being and pose unique challenges due to their wide range of symptoms. Patient-reported outcomes (PROs) provide valuable insights into how these diseases influence different dimensions of HRQoL, supporting personalized healthcare approaches. Methodology: In this cross-sectional study, we examined HRQoL in 213 patients with rheumatologic diseases, including, among others, rheumatoid arthritis, localized pain disorders, connective tissue diseases, and rarer conditions such as vasculitis, using the EQ5D-5L and the Patient-Reported Outcomes Measurement Information System (PROMIS ® ) as well as Pain and HRQoL specific PROs. We provided PROMIS health domain scores of key health aspects such as physical function, fatigue, pain interference, and social participation. Additionally, we compared HRQoL and PROMIS domain scores with a German general population reference sample and conducted exploratory comparisons across the three most frequent principal diagnosis groups: systemic sclerosis, rheumatoid arthritis, and vasculitis. Moreover, we investigated which patient-reported health domains were most strongly associated with HRQoL in these diseases. Penalized regression models with elastic net regularization were used to identify stable predictors of HRQoL, followed by a pooled linear regression model for interpretation. Results: Individuals with rheumatic diseases had significantly lower HRQoL than the general population (EQ-5D-5L VAS mean: 55.4 versus 73.2). PROMIS T-scores indicated markedly reduced Physical Function (M = 36.5, SD = 9.6) and elevated pain interference (M = 61.7, SD = 9.2). Penalized regression analyses identified Physical Function, Fatigue, Ability to Participate in Social Roles and Activities as stable predictors of EQ-5D-5L VAS. Higher Physical Function and Social Participation were associated with higher HRQoL, whereas higher Fatigue was associated with lower HRQoL. Conclusions: These results highlight the importance of PROs in understanding the patient experience in rheumatologic disease and identifying individual needs. Routine assessment of HRQoL domains may help recognize unmet needs and support individualized care in rheumatology.
- 10 July 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessUnderstanding Health-related quality of life in rheumatologic diseases: insights from PROMIS® health domains
Background: Rheumatologic diseases significantly impact health-related quality of life (HRQoL), affecting physical, mental, and social well-being and pose unique challenges due to their wide range of symptoms. Patient-reported outcomes (PROs) provide valuable insights into how these diseases influence different dimensions of HRQoL, supporting personalized healthcare approaches. Methodology: In this cross-sectional study, we examined HRQoL in 213 patients with rheumatologic diseases, including, among others, rheumatoid arthritis, localized pain disorders, connective tissue diseases, and rarer conditions such as vasculitis, using the EQ5D-5L and the Patient-Reported Outcomes Measurement Information System (PROMIS ® ) as well as Pain and HRQoL specific PROs. We provided PROMIS health domain scores of key health aspects such as physical function, fatigue, pain interference, and social participation. Additionally, we compared HRQoL and PROMIS domain scores with a German general population reference sample and conducted exploratory comparisons across the three most frequent principal diagnosis groups: systemic sclerosis, rheumatoid arthritis, and vasculitis. Moreover, we investigated which patient-reported health domains were most strongly associated with HRQoL in these diseases. Penalized regression models with elastic net regularization were used to identify stable predictors of HRQoL, followed by a pooled linear regression model for interpretation. Results: Individuals with rheumatic diseases had significantly lower HRQoL than the general population (EQ-5D-5L VAS mean: 55.4 versus 73.2). PROMIS T-scores indicated markedly reduced Physical Function (M = 36.5, SD = 9.6) and elevated pain interference (M = 61.7, SD = 9.2). Penalized regression analyses identified Physical Function, Fatigue, Ability to Participate in Social Roles and Activities as stable predictors of EQ-5D-5L VAS. Higher Physical Function and Social Participation were associated with higher HRQoL, whereas higher Fatigue was associated with lower HRQoL. Conclusions: These results highlight the importance of PROs in understanding the patient experience in rheumatologic disease and identifying individual needs. Routine assessment of HRQoL domains may help recognize unmet needs and support individualized care in rheumatology.
- 8 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (857) , eadz2015
Cytokine-mediated activation of kidney-infiltrating CD8 + T cells enables their contribution to inflammation in human lupus nephritis
Proliferative lupus nephritis (LN) is triggered by deposition of autoantibodies in glomeruli and paralleled by a T cell–rich kidney infiltrate. Although these T cells have been attributed to the propagation of tissue injury, it is unclear how they are activated and whether T cell autoreactivity drives local inflammation. Kidney-infiltrating T cells are also observed in urine, where they have high resemblance to interstitial T cells. Therefore, urinary T cells are a proxy for investigating tissue pathogenesis. Here, we analyzed urinary T cells to elucidate whether a kidney-specific T cell autoimmune reaction contributes to tubulointerstitial inflammation in LN. Using single-cell RNA sequencing, we compared transcriptomes and clonotypes of T cells from the blood and urine of patients with active LN and showed that urinary T cells were mostly activated CD8 effector memory cells recruited from a circulating CX3CR1 + subset. Several urinary CD8 T cell clones were expanded. However, upon in vitro testing of their T cell receptors, we did not observe autoreactivity against autologous tubular epithelial cells. Instead, ~20% of expanded clonotypes were Epstein-Barr virus–specific or cytomegalovirus-specific, but respective viral antigens were undetectable in kidney biopsies or urine. Conversely, kidney-infiltrating T cells had access to interleukin-15 and interferon-β (IFN-β), and stimulation with these cytokines was sufficient to trigger degranulation and production of tumor necrosis factor, IFN-γ, and granzyme K. Together, these results show that CD8 + CX3CR1 + T cells are recruited into the kidney in LN, where they are activated by cytokines, enabling them to contribute to local inflammation.
- 8 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (857) , eadz2015
Cytokine-mediated activation of kidney-infiltrating CD8 + T cells enables their contribution to inflammation in human lupus nephritis
Proliferative lupus nephritis (LN) is triggered by deposition of autoantibodies in glomeruli and paralleled by a T cell–rich kidney infiltrate. Although these T cells have been attributed to the propagation of tissue injury, it is unclear how they are activated and whether T cell autoreactivity drives local inflammation. Kidney-infiltrating T cells are also observed in urine, where they have high resemblance to interstitial T cells. Therefore, urinary T cells are a proxy for investigating tissue pathogenesis. Here, we analyzed urinary T cells to elucidate whether a kidney-specific T cell autoimmune reaction contributes to tubulointerstitial inflammation in LN. Using single-cell RNA sequencing, we compared transcriptomes and clonotypes of T cells from the blood and urine of patients with active LN and showed that urinary T cells were mostly activated CD8 effector memory cells recruited from a circulating CX3CR1 + subset. Several urinary CD8 T cell clones were expanded. However, upon in vitro testing of their T cell receptors, we did not observe autoreactivity against autologous tubular epithelial cells. Instead, ~20% of expanded clonotypes were Epstein-Barr virus–specific or cytomegalovirus-specific, but respective viral antigens were undetectable in kidney biopsies or urine. Conversely, kidney-infiltrating T cells had access to interleukin-15 and interferon-β (IFN-β), and stimulation with these cytokines was sufficient to trigger degranulation and production of tumor necrosis factor, IFN-γ, and granzyme K. Together, these results show that CD8 + CX3CR1 + T cells are recruited into the kidney in LN, where they are activated by cytokines, enabling them to contribute to local inflammation.
- Open Access
- 18 March 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 194, 112233
Standardizing physical function across assessment types: Three versions of the physical performance test were linked to the PROMIS physical function metric in diverse populations
- 18 March 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 194, 112233
Open AccessStandardizing physical function across assessment types: Three versions of the physical performance test were linked to the PROMIS physical function metric in diverse populations
- Open Access
- 3 January 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Bridging patient-reported outcomes and performance assessments in older adults: linking the Short Physical Performance Battery to the standardised PROMIS Physical Function scale
Background: Assessment of physical function, a key outcome in geriatric research, relies on either patient-reported or performance-based assessments. While several patient-reported instruments have been successfully linked to the standardised Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function scale, commonly used performance-based tools, such as the Short Physical Performance Battery (SPPB), remain uncalibrated to this scale. This lack of standardisation limits interpretability, comparability, and integration of physical function data across instruments, studies, and clinical settings. Objective: To link SPPB scores to the PROMIS Physical Function T-score metric in older adults. Methods: This analysis is part of the Standardizing-PF project, a prospectively designed cross-sectional study examining the possibility of mapping patient-reported and performance-based assessments onto a common scale. In the present study, 556 older adults (mean age 74 years) from different clinical and community-based settings subsequently completed a generic 20-item PROMIS Physical Function short form (PROMIS-PF20a) and the SPPB. Assumptions of item response theory modelling were investigated. We estimated a unidimensional item response theory-based linking model and derived cross-walks to convert SPPB scores into standardised PROMIS PF T-scores. Results: SPPB and PROMIS-PF20a were highly correlated (latent correlation = 0.89); assumptions of item response theory modelling were fulfilled. After linking, agreement between observed and linked T-scores was stable across several subsamples. Conclusions: The SPPB can be meaningfully linked to the PROMIS PF T-score metric, enabling standardised interpretation, comparison, and aggregation of performance-based and self-reported physical function in older adults. We provide a user-friendly score cross-walk table to facilitate application in clinical practise and standardisation in geriatric research.
- 3 January 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Open AccessBridging patient-reported outcomes and performance assessments in older adults: linking the Short Physical Performance Battery to the standardised PROMIS Physical Function scale
Background: Assessment of physical function, a key outcome in geriatric research, relies on either patient-reported or performance-based assessments. While several patient-reported instruments have been successfully linked to the standardised Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function scale, commonly used performance-based tools, such as the Short Physical Performance Battery (SPPB), remain uncalibrated to this scale. This lack of standardisation limits interpretability, comparability, and integration of physical function data across instruments, studies, and clinical settings. Objective: To link SPPB scores to the PROMIS Physical Function T-score metric in older adults. Methods: This analysis is part of the Standardizing-PF project, a prospectively designed cross-sectional study examining the possibility of mapping patient-reported and performance-based assessments onto a common scale. In the present study, 556 older adults (mean age 74 years) from different clinical and community-based settings subsequently completed a generic 20-item PROMIS Physical Function short form (PROMIS-PF20a) and the SPPB. Assumptions of item response theory modelling were investigated. We estimated a unidimensional item response theory-based linking model and derived cross-walks to convert SPPB scores into standardised PROMIS PF T-scores. Results: SPPB and PROMIS-PF20a were highly correlated (latent correlation = 0.89); assumptions of item response theory modelling were fulfilled. After linking, agreement between observed and linked T-scores was stable across several subsamples. Conclusions: The SPPB can be meaningfully linked to the PROMIS PF T-score metric, enabling standardised interpretation, comparison, and aggregation of performance-based and self-reported physical function in older adults. We provide a user-friendly score cross-walk table to facilitate application in clinical practise and standardisation in geriatric research.
- 1 January 2026
- Published by Georg Thieme Verlag KG
Seltene Systemerkrankungen
- Open Access
- 6 December 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (4) , 462-464
Systemic sclerosis triggered by bleomycin: a 5-year follow-up
- 6 December 2025
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (4) , 462-464
Open AccessSystemic sclerosis triggered by bleomycin: a 5-year follow-up
- 22 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Identification of a distinctive gene signature associated with disease activity in granulomatous myositis
Objectives: Granulomatous myositis (GM) is defined by focal collections of activated macrophages that fuse to form multinucleated cells that aggregate into granulomas within skeletal muscle. This study aimed to elucidate the pathophysiology of GM by defining its specific transcriptomic profile. Methods: Bulk RNA sequencing was performed on 722 muscle biopsies, including 38 from patients with GM, other myopathies and healthy comparators. Spatial transcriptomics and immunohistochemistry assays were used to identify the location of specific transcripts and proteins within the tissue. Results: We conducted a systematic analysis of the inflammatory pathways implicated in GM. This analysis revealed that GM muscle biopsies are characterized by elevated levels of IFNγ, IFNγ-inducible genes and proinflammatory cytokine genes including IL1B, TNF and TGFB1. Additionally, we identified a specific gene signature in GM, comprising 1293 genes that were significantly upregulated and 256 significantly downregulated. These genes were strongly correlated with transcriptomic markers of disease activity. Using this gene signature, support vector machine models accurately identified GM, achieving an area under the curve of 99.6% (99.0–99.9%) and an accuracy of 98.6% (98.2–98.9%). Among the identified genes, CHIT1 emerged as the most significantly upregulated gene, with its expression strongly correlating with disease severity. Furthermore, CHIT1 was detected at both the RNA and protein levels in granulomas and giant cells. Conclusion: GM is transcriptomically characterized by a strong IFNγ signature and overexpression of proinflammatory cytokines, including IL1B, TNF and TGFB1. Additionally, it exhibits a unique transcriptomic profile, including CHIT1, which correlates with disease activity.
- 22 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Identification of a distinctive gene signature associated with disease activity in granulomatous myositis
Objectives: Granulomatous myositis (GM) is defined by focal collections of activated macrophages that fuse to form multinucleated cells that aggregate into granulomas within skeletal muscle. This study aimed to elucidate the pathophysiology of GM by defining its specific transcriptomic profile. Methods: Bulk RNA sequencing was performed on 722 muscle biopsies, including 38 from patients with GM, other myopathies and healthy comparators. Spatial transcriptomics and immunohistochemistry assays were used to identify the location of specific transcripts and proteins within the tissue. Results: We conducted a systematic analysis of the inflammatory pathways implicated in GM. This analysis revealed that GM muscle biopsies are characterized by elevated levels of IFNγ, IFNγ-inducible genes and proinflammatory cytokine genes including IL1B, TNF and TGFB1. Additionally, we identified a specific gene signature in GM, comprising 1293 genes that were significantly upregulated and 256 significantly downregulated. These genes were strongly correlated with transcriptomic markers of disease activity. Using this gene signature, support vector machine models accurately identified GM, achieving an area under the curve of 99.6% (99.0–99.9%) and an accuracy of 98.6% (98.2–98.9%). Among the identified genes, CHIT1 emerged as the most significantly upregulated gene, with its expression strongly correlating with disease severity. Furthermore, CHIT1 was detected at both the RNA and protein levels in granulomas and giant cells. Conclusion: GM is transcriptomically characterized by a strong IFNγ signature and overexpression of proinflammatory cytokines, including IL1B, TNF and TGFB1. Additionally, it exhibits a unique transcriptomic profile, including CHIT1, which correlates with disease activity.
- Open Access
- 12 May 2025
- Published by Wiley in Brain Pathology
- Vol. 35 (5) , e70015
Correspondence to: Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome
- 12 May 2025
- Published by Wiley in Brain Pathology
- Vol. 35 (5) , e70015
Open AccessCorrespondence to: Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome
- 8 April 2025
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 22 (4) , 186-194
Rheumatoide Arthritis: Screening für Lungenmanifestationen und Management
- 8 April 2025
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 22 (4) , 186-194
Rheumatoide Arthritis: Screening für Lungenmanifestationen und Management
- 16 May 2024
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 99 (7) , 1046-1057
Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study
- 16 May 2024
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 99 (7) , 1046-1057
Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study